M K Proteins Limited

M K Proteins Limited

3.79
INR
-0.08
(-2.07%)
0.13EPS
36.49P/E
1.77BMarket Cap
M K Proteins Limited
NSE:MKPL
(National Stock Exchange of India)

Recent

price

3.79

P/E

ratio

36.49

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
2.28
3.24
3.28
20.04
4.38
12.43
15.51
24.86
6.82
8.39
6.57
7.13
10.13
10.52
Revenue per Share
0.01
0.01
0.02
0.1
0.03
0.13
0.15
0.83
0.27
0.29
0.3
0.22
0.18
0.13
Basic EPS, GAAP
-0.48
-0.22
0.28
-0.83
-0.12
0.51
-0.36
0.44
-0.31
-0.16
0.71
-0.49
0.09
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.03
0.05
0.07
0.09
0.11
0.46
0.5
0.78
1.04
1.33
1.63
1.85
2.03
- -
Book Value per Share
0.03
0.05
0.07
0.09
0.11
0.46
0.5
0.78
1.04
1.33
1.63
1.85
2.03
- -
Tangible Book Value per Share
375
375
375
72
375
125
125
125
375
375
374
375
375
364
Basic Weighted Avg Shares
854
1,217
1,232
1,448
1,645
1,555
1,940
3,111
2,559
3,149
2,456
2,677
3,803
3,831
Sales/Revenue/Turnover
1.64
2.03
2.85
2.27
2.23
2.44
1.88
4.85
5.78
5.34
6.7
4.55
2.9
2.07
Operating Margin (%)
2
4
7
9
12
12
12
9
9
8
5
4
4
5
Depreciation Expense
5
5
8
7
10
16
18
104
102
109
112
84
68
47
Net Income, GAAP
32.36
32.2
31.85
31.26
34.83
28.09
25.63
27.46
27.47
27.05
27.52
26.67
27.26
28.06
Effective Tax Rate (%)
0.62
0.41
0.68
0.5
0.6
1.06
0.94
3.34
3.98
3.47
4.57
3.14
1.8
1.23
Profit Margin (%)
22
53
36
41
90
138
192
307
376
490
519
595
657
- -
Working Capital
50
101
73
80
121
15
40
44
37
35
10
18
20
- -
LT Debt
12
17
25
33
43
171
189
293
389
499
611
695
763
- -
Total Equity
- -
2.01
3.21
2.74
7.23
6.85
5.83
20.18
15.26
13.4
12.96
9.25
7.2
- -
Return on Invested Capital (%)
- -
6.76
9.08
8.63
7.37
6.97
6.31
21.03
16.45
14.27
13.58
9.73
7.38
- -
Return on Capital (%)
- -
33.94
39.43
24.86
26.2
15.36
10.07
43.03
29.85
24.64
20.21
12.87
9.37
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
352
- -
LT Borrowings
- -
10
- -
LT Finance Leases
- -
9
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
375
375
375
Market Capitalization
2,279
1,453
1,768

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,182
- -
Cash, Cash Equivalents & STI
- -
4
- -
Accounts Receivable, Net
- -
21
- -
Inventories
- -
1,098
- -
Total Current Liabilities
- -
525
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
352
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
53.39%
21.37%
9.84%
Free Cash Flow
-201.29%
-240.07%
-119.28%
Net Income, GAAP
53.6%
-7.17%
-18.68%
Sales/Revenue/Turnover
14.51%
6.87%
42.07%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
573
337
395
1,372
2,677
2026
1,149
324
896
1,459
3,803
2027
1,152
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.07
0.04
0.04
0.07
0.22
2026
0.09
0.02
0.04
0.03
0.18
2027
0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Business
M. K. Proteins Limited manufactures and trades vegetable refined oils and by-products in India; its core products include refined rice bran oil, sunflower oil, cotton seed oil, soya bean oil, palm oil, and canola oil, along with by-products such as rice bran fatty acid oil, rice bran wax, gums, and spent earth. The company, founded in 2012 and headquartered in Ambala, Haryana, operates a refining facility with 250 tons per day capacity at Village Garnala, Naraingarh Road; it imports crude oils for processing, trades in both edible and non-edible oils, and focuses on high-quality production with controlled fibre content free from residues, ash, sand, and silica for markets in North India. As part of the Shree Ganesh Fats Group established in 1958, it underwent conversion from private to public limited company in 2017; recent developments include the appointment of Mr. Deepak Khetarpal as additional independent director in August 2025, pending shareholder approval, and submission of integrated financial filings for the year ended March 31, 2025 pursuant to SEBI regulations.